TrialEBioMedicine2024

Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma.

Loic Verlingue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.